The findings revealed that ondansetron pharmacokinetic exposure increased proportionally across a threefold AD04 dose range, between AD04 0.33 mg tablets and the marketed ondansetron 4 mg tablets.

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker.

Medicinal Chemistry Research Team, New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Suwon 16229, Republic of Korea Nonclinical Research Team, New Drug ...

Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China University of Chinese Academy of Sciences, Beijing 100049, China ...

The college admissions process is undergoing significant changes, driven by technological advances, evolving policies, and a shift in priorities. As students and families navigate this evolving ...